Healing of mouth soft tissues using topically applied gel.

Effectiveness of recombinant human epidermal growth factor (rhEGF) in healing of palatal donor sites post soft tissue graft harvesting - A double blinded parallel arm clinical trial (EGFTRIAL)

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/01/049177

Enrollment

100

Registered

2023-01-24

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K069- Disorder of gingiva and edentulousalveolar ridge, unspecified

Interventions

Intervention1: rh EGF Group: After palatal soft tissue graft harvesting for various indications, the patients will be subjected for topical application of recombinant human epidermal growth factor gel

Eligibility

Inclusion criteria

Inclusion criteria: Patients undergoing palatal soft tissue graft harvesting procedure for various indications as required

Exclusion criteria

Exclusion criteria: Other than ASA - 1 Physical status Known allergy to methyl parapen / propyl paraben Expecting / Planned / Pregnant women Lactating mothers Unwilling for follow ups

Design outcomes

Primary

Measure	Time frame
Modified Landrys index of healing Area of the wound at Donor Site Numerical Rating Scale for Pain AssessmentTimepoint: Baseline First Day Second day Third Day Fourth Day Fifth Day First Month and Third Month	—

Secondary

Measure	Time frame
Faster Healing Early Reepithelization Early wound closure Less post operative painTimepoint: Baseline and three months	—

Countries

India

Contacts

Public ContactRUCHI HARISH

ARMY DENTAL CENTRE RESEARCH AND REFERRAL DELHI

ruchiharish@gmail.com9679628202

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026